1. Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo.
Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. (A) HeLa tumor volumes after CSSD-9 treatment at different doses. When tumors reached 100 to 200 mm3 in size, mice were treated with 10 and 20 μg of CSSD-9 via I.T. or I.V. injection. Tumor sizes were measured every 3 days, and tumor volumes were calculated. (B) SiHa, A549, and HepG2 tumor images and growth curves after CSSD-9 treatment by I.V. and I.T. injection. (C) Visible metastatic nodules on the surface of lungs in the control and CSSD-9–treated mice (top). Representative figures of hematoxylin and eosin (H&E) staining were performed on serial sections of metastatic tumors in the lungs. Scale bars, 50 μm. (D) Number of metastatic lung nodules was quantified in the control and CSSD-9 treatment groups. (E) miR-9 expression in the control and CSSD-9 groups was detected by qRT-PCR after lysis of tumor tissues and RNA extraction. (F) mRNA expression of KLF17, CDH1, and LASS2 in control and CSSD-9 treatment groups was detected by qRT-PCR. (G) Expression of KLF17, CDH1, and LASS2 was confirmed with Western blot analysis after lysis of tumor tissues. (H) Left: In vivo fluorescence imaging of a BALB/c nude mouse that received I.V. injection of A549-GFP cells and treated with CSSD-9 by I.V. injection. Right: CTCs were detected by flow cytometry. (I) Infiltration of CD8+ T cell (CD3+CD8+) and IFN-γ+ cell percentage in the tumor tissues after CSSD-9 treatment by I.T. or I.V. injection. (J) Percentages of MDSCs in tumor tissues, bone marrow (BM), and spleen after CSSD-9 treatment. All data are represented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, **** P <
Jing Meng et al., Sci Transl Med 2018;10:eaao6321
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works